Compare Stocks: BCYC, ALVO, REPL, and JBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$4.05 -1.0%	$3.67	$2.94 ▼ $9.25	$1.23B	0.18	869,565 shs	607,247 shs
BCYC Bicycle Therapeutics	$3.90 -2.0%	$4.10	$3.74 ▼ $9.16	$277.85M	1.55	305,130 shs	468,018 shs
JBIO Jade Biosciences	$24.71 +3.8%	$20.23	$6.67 ▼ $28.00	$1.51B	1.49	803,573 shs	1.48 million shs
REPL Replimune Group	$14.97 -1.4%	$10.66	$1.50 ▼ $15.70	$1.28B	0.88	8.22 million shs	2.40 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	-0.98%	+6.30%	+19.82%	+22.36%	-54.80%
BCYC Bicycle Therapeutics	-2.01%	-6.47%	-7.58%	-12.36%	-46.94%
JBIO Jade Biosciences	+3.78%	+12.52%	+13.04%	+5.82%	+237.11%
REPL Replimune Group	-1.45%	+24.13%	+54.65%	+186.78%	+193.82%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$4.05 -1.0%	$3.67	$2.94 ▼ $9.25	$1.23B	0.18	869,565 shs	607,247 shs
BCYC Bicycle Therapeutics	$3.90 -2.0%	$4.10	$3.74 ▼ $9.16	$277.85M	1.55	305,130 shs	468,018 shs
JBIO Jade Biosciences	$24.71 +3.8%	$20.23	$6.67 ▼ $28.00	$1.51B	1.49	803,573 shs	1.48 million shs
REPL Replimune Group	$14.97 -1.4%	$10.66	$1.50 ▼ $15.70	$1.28B	0.88	8.22 million shs	2.40 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	-0.98%	+6.30%	+19.82%	+22.36%	-54.80%
BCYC Bicycle Therapeutics	-2.01%	-6.47%	-7.58%	-12.36%	-46.94%
JBIO Jade Biosciences	+3.78%	+12.52%	+13.04%	+5.82%	+237.11%
REPL Replimune Group	-1.45%	+24.13%	+54.65%	+186.78%	+193.82%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	2.14	Hold	$7.60	87.65% Upside
BCYC Bicycle Therapeutics	2.44	Hold	$13.86	255.31% Upside
JBIO Jade Biosciences	2.90	Moderate Buy	$51.75	109.43% Upside
REPL Replimune Group	2.60	Moderate Buy	$11.86	-20.79% Downside

Current Analyst Ratings Breakdown

Latest BCYC, ALVO, REPL, and JBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	ALVO Alvotech	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/12/2026	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/11/2026	REPL Replimune Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	JBIO Jade Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$48.00
8/10/2026	JBIO Jade Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$45.00 ➝ $47.00
8/10/2026	JBIO Jade Biosciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$74.00 ➝ $77.00
8/7/2026	REPL Replimune Group	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$12.00
8/7/2026	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$17.00 ➝ $20.00
8/4/2026	REPL Replimune Group	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform
8/4/2026	REPL Replimune Group	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$11.00 ➝ $17.00
7/31/2026	REPL Replimune Group	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$9.00 ➝ $12.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$588.90M	2.08	$0.22 per share	18.40	($0.94) per share	-4.31
BCYC Bicycle Therapeutics	$72.86M	3.74	N/A	N/A	$7.31 per share	0.53
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$6.74 per share	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	$2.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	$27.92M	-$0.25	N/A	12.66	N/A	-14.36%	-11.92%	-7.59%	8/19/2026 (Estimated)
BCYC Bicycle Therapeutics	-$218.96M	-$2.73	N/A	N/A	N/A	-311.11%	-33.22%	-27.79%	10/29/2026 (Estimated)
JBIO Jade Biosciences	-$127.41M	-$1.92	N/A	N/A	N/A	N/A	-56.87%	-52.74%	N/A
REPL Replimune Group	-$313.94M	-$3.38	N/A	N/A	N/A	N/A	-128.57%	-82.35%	10/29/2026 (Estimated)

Latest BCYC, ALVO, REPL, and JBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2026	Q2 2026	ALVO Alvotech	-$0.0526	N/A	N/A	N/A	$103.00 million	N/A
8/14/2026	Q1 2027	REPL Replimune Group	-$0.6940	-$0.72	-$0.0260	-$0.72	$13.60 million	N/A
8/10/2026	Q2 2026	JBIO Jade Biosciences	-$0.66	-$0.76	-$0.10	-$0.76	N/A	N/A
7/30/2026	Q2 2026	BCYC Bicycle Therapeutics	-$0.5756	-$0.72	-$0.1444	-$0.72	$4.22 million	$0.63 million
6/29/2026	Q4 2026	REPL Replimune Group	-$0.6613	-$0.76	-$0.0988	-$0.76	$3.57 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.76	0.88
BCYC Bicycle Therapeutics	N/A	12.08	12.08
JBIO Jade Biosciences	N/A	14.29	14.29
REPL Replimune Group	0.63	4.79	4.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
BCYC Bicycle Therapeutics	86.15%
JBIO Jade Biosciences	N/A
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	0.46%
BCYC Bicycle Therapeutics	22.00%
JBIO Jade Biosciences	23.06%
REPL Replimune Group	5.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,460	301.81 million	300.42 million	Not Optionable
BCYC Bicycle Therapeutics	240	69.81 million	54.45 million	Optionable
JBIO Jade Biosciences	20	63.60 million	37.98 million	N/A
REPL Replimune Group	210	84.03 million	79.49 million	Optionable

BCYC, ALVO, REPL, and JBIO Headlines

Recent News About These Companies

Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings Results

4 hours ago | marketbeat.com

Replimune Group, Inc.: Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

August 14 at 11:30 AM | finanznachrichten.de

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

August 14 at 10:37 AM | globenewswire.com

Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

August 14 at 10:30 AM | globenewswire.com

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

August 14 at 8:00 AM | globenewswire.com

Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment

August 13 at 11:06 PM | finance.yahoo.com

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - REPL

August 13 at 8:15 PM | businesswire.com

REPL SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Replimune Group, Inc. Investors - Contact Kirby McInerney LLP by October 5, 2026

August 13 at 8:00 PM | globenewswire.com

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

August 13 at 12:37 PM | prnewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

August 13 at 12:00 PM | prnewswire.com

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

August 13 at 11:18 AM | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

August 13 at 10:00 AM | prnewswire.com

Replimune Group (NASDAQ:REPL) CAO Andrew Schwendenman Sells 7,632 Shares

August 13 at 7:36 AM | insidertrades.com

Replimune Group (NASDAQ:REPL) CAO Sells 7,632 Shares

August 12 at 7:22 PM | marketbeat.com

Replimune Group (NASDAQ:REPL) Insider Sells 11,447 Shares of Stock

August 12 at 7:22 PM | marketbeat.com

Emily Luisa Hill Sells 11,448 Shares of Replimune Group (NASDAQ:REPL) Stock

August 12 at 7:22 PM | marketbeat.com

Insider Selling: Replimune Group (NASDAQ:REPL) CEO Sells 39,341 Shares

August 12 at 7:21 PM | marketbeat.com

REPL Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Replimune Group, Inc. Securities Class Action

August 12 at 3:06 PM | globenewswire.com

Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL

August 12 at 10:07 AM | prnewswire.com

REPL INVESTOR NOTICE: Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead the Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

August 12 at 7:30 AM | globenewswire.com

Replimune Group (NASDAQ:REPL) Sets New 12-Month High - Here's Why

August 12 at 4:19 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BCYC, ALVO, REPL, and JBIO Company Descriptions

Alvotech NASDAQ:ALVO

$4.05 -0.04 (-0.98%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$4.03 -0.02 (-0.62%)

As of 08/14/2026 07:50 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Bicycle Therapeutics NASDAQ:BCYC

$3.90 -0.08 (-2.01%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.92 +0.02 (+0.49%)

As of 08/14/2026 07:34 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Jade Biosciences NASDAQ:JBIO

$24.71 +0.90 (+3.78%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$24.72 +0.00 (+0.02%)

As of 08/14/2026 07:34 PM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Replimune Group NASDAQ:REPL

$14.97 -0.22 (-1.45%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$14.72 -0.26 (-1.70%)

As of 08/14/2026 07:44 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCYC, ALVO, REPL, and JBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCYC, ALVO, REPL, and JBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCYC, ALVO, REPL, and JBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BCYC, ALVO, REPL, and JBIO Company Descriptions

Alvotech NASDAQ:ALVO

Bicycle Therapeutics NASDAQ:BCYC

Jade Biosciences NASDAQ:JBIO

Replimune Group NASDAQ:REPL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCYC, ALVO, REPL, and JBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCYC, ALVO, REPL, and JBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCYC, ALVO, REPL, and JBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BCYC, ALVO, REPL, and JBIO Company Descriptions

Alvotech NASDAQ:ALVO

Bicycle Therapeutics NASDAQ:BCYC

Jade Biosciences NASDAQ:JBIO

Replimune Group NASDAQ:REPL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools